印度赫赛汀

【印度赫赛汀说明书，怎么吃？】

赫赛汀（印度）又名曲妥珠单抗 Hertraz，赫赛汀适用于Hertraz适用于治疗HER2过表达的转移性乳腺癌和转移性胃癌。 1、Hertraz作为单一药物治疗已接受过1个或多个化疗方案的转移性乳腺癌。 2、Hertraz与紫杉类药物合用治疗未接受过化疗的转移性乳腺癌。 3、Hertraz用于早期乳腺癌。 4、转移性胃癌：Hertraz联合卡培他滨或5-氟尿嘧啶和顺铂适用于既往未接受过针对转移性疾病治疗的HER2过度表达的转移性胃腺癌或胃食管交界腺癌患者。 的治疗，赫赛汀用法及注意事项,:【用法用量】 （静脉滴注，早期乳腺癌、转移性乳腺癌和转移性胃癌的初始剂量和维持剂量略有不同，具体根据医生的意见） 1、转移性乳腺癌：建议Hertraz的初次负荷量为4mg/kg。静脉输注90 分钟以...

【用法用量】
 
（静脉滴注，早期乳腺癌、转移性乳腺癌和转移性胃癌的初始剂量和维持剂量略有不同，具体根据医生的意见）
 
1、转移性乳腺癌：建议Hertraz的初次负荷量为4mg/kg。静脉输注90 分钟以上。应观察病人是否出现发热，寒战或其它输注相关症状（见不良反应）。Hertraz维持剂量：建议每周用量为2mg/kg。
 
2、乳腺癌辅助治疗：在完成所有化疗后开始曲妥珠单抗治疗。曲妥珠单抗的给药方案为：8mg/kg 初始负荷量后接着每 3 周 6 mg/kg 维持量，静脉滴注约 90 分钟。
 
3、早期乳腺癌：初始负荷剂量为8mg/kg，随后6mg/kg每三周给药一次。
 
4、转移性胃癌：建议采用每三周一次的给药方案，初始负荷剂量为8mg/kg，随后6mg/kg每三周给药一次。首次输注时间约为90分钟。如果患者在首次输注时耐受性良好，后续输注可改为30分钟。维持治疗直至疾病发展。

 
【不良反应】
 
最常见的不良反应是：发热、恶心、呕吐、输注反应、腹泻、感染、咳嗽加重、头痛、乏力、呼吸困难、皮疹、中性粒细胞减少症、贫血和肌痛。
 
心肌毒性，输注反应，化疗引起的中性粒细胞减少症加重，肺毒性。
 
需要中断或停止曲妥珠单抗治疗的不良反应包括：充血性心衰、左心室功能明显下降、严重的输注反应。
 
 
 
【赫赛汀在应用过程中的护理问题】
 
1、药品需要保存在2-8℃的冰箱内保存，并且严格按照无菌原则进行药液配置。
 
2、首次应用赫赛汀的患者应该严密观察，并且给与心电监护，注意有无过敏反应，及其他不良反应症状。
 
3、在使用过程中两个重要的不良反应是药品过敏反应和心功能减退，如患者出现寒战发热、恶心呕吐、呼吸困难等，应立即停止滴注，并对症处理。
 
4、在应用前应注意评估患者心功能，严重心脏病者，不宜应用。


USES OF HERTRAZ INJECTION
Breast cancer
Stomach cancer

HERTRAZ INJECTION SIDE EFFECTS
Common
Nausea
Headache
Rash
Insomnia (difficulty in sleeping)
Infection
Upper respiratory tract infection
Fatigue
Fever
Anemia (low number of red blood cells)
Chills
Diarrhea
Cough
Weight loss
Taste change
Mucosal inflammation
Stomatitis (Inflammation of the mouth)
Heart failure
Decreased blood cells (red cells, white cells, and platelets)
Common cold

HOW TO USE HERTRAZ INJECTION
Your doctor or nurse will give you this medicine. Kindly do not self administer.

HOW HERTRAZ INJECTION WORKS
Hertraz 440 mg Injection is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.

HERTRAZ INJECTION RELATED WARNINGS
warnings
Alcohol
Interaction with alcohol is unknown. Please consult your doctor.
warnings
Pregnancy

WEIGH RISKS VS BENEFITS
Hertraz 440 mg Injection is unsafe to use during pregnancy.
There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk, for example in life-threatening situations. Please consult your doctor.

warnings
Lactation
CAUTION
Hertraz 440 mg Injection is probably unsafe to use during lactation. Limited human data suggest that the drug could represent a significant risk to the baby.

warnings
Driving
It is not known whether Hertraz 440 mg Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

warnings
Kidney
Hertraz 440 mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Hertraz 440 mg Injection may not be needed in these patients. Please consult your doctor.

warnings
Liver
There is limited information available on the use of Hertraz 440 mg Injection in patients with liver disease. Please consult your doctor.

WHAT IF YOU MISS A DOSE OF HERTRAZ INJECTION?
If you miss a dose of Hertraz 440 mg Injection, please consult your doctor.